Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6763–6768 | Cite as

Diagnostic value of CD117 in differential diagnosis of acute leukemias

  • Abbas Ahmadi
  • Ali-Akbar Poorfathollah
  • Mahnaz Aghaiipour
  • Mansour Rezaei
  • Mahin Nikoo-ghoftar
  • Mohammad Abdi
  • Alireza Gharib
  • Amir Amini
Research Article

Abstract

C-kit receptor (CD117) and its ligand, stem cell factor, play a key role in normal hematopoiesis. It has been demonstrated that its expression extremely increases in leukemias with myeloid commitment. We analyzed findings on CD117 expression together with other myeloid related markers in 203 de novo acute leukemias, referred to Iranian immunophenotyping centers: Iranian Blood Transfusion Organization (IBTO) and Baghiatallah Hospital (BH). All cases were characterized based on the French American British cooperative group (FAB) and European Group for Immunological Classification of Leukemias (EGIL). The cases comprised of 111 acute myeloblastic leukemia (AML), 86 acute lymphoblastic leukemia (ALL), and 6 acute undifferentiated leukemia (AUL). CD117 was positive in 75 % of AML and 50 % of AUL, whereas none of the ALL cases was positive for this marker. Although CD117 was positive in 100 % of M5a cases, no M5b positive was found (p = 0.036). The calculated specificity for myeloid involvement was 100 % for CD117 and CD33, and 98 % for CD13 and CD15 (p < 0.001). The calculated sensitivity for myeloid involvement was 83, 76, 64, and 41 % for CD13, CD117, CD33, and CD15, respectively (p < 0.001). We concluded that CD117 expression is a specific and rather sensitive marker for differential diagnosis between AML and ALL, and except for M5 subtypes, it fails to determine FAB subtypes; lack of expression in M5 can identify M5b. Therefore, it should be included in the routine primary panel for diagnosis of acute leukemias.

Keywords

Acute Leukemia Immunophenotyping CD117 AML ALL 

Notes

Acknowledgments

The authors wish to thank all the patients for participating in the study. Financial supports for this study were provided by the Iranian Blood Transfusion Organization, Tehran, Iran.

Conflicts of interest

None

References

  1. 1.
    Dirnhofer S, Zimpfer A, Went P. The diagnostic and predictive role of kit (cd117). Ther Umsch. 2006;63:273–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Scharnhorst V, Wals J, Beverloo HB, Langerak AW, van der Velden VH. Mutation of flt3 is not a general phenomenon in cd117-positive t-all. Leuk Res. 2006;30:245–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Wozniak J, Kopec-Szlezak J. C-kit receptor (cd117) expression on myeloblasts and white blood cell counts in acute myeloid leukemia. Cytometry Part B, Clin Cytom. 2004;58:9–16.CrossRefGoogle Scholar
  4. 4.
    Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (cd117) molecule in normal and malignant hematopoiesis. Leukemia Lymphoma. 1998;30:459–66.PubMedGoogle Scholar
  5. 5.
    Sel S, Schilling UM, Nass N, Simm A, Garreis F, Knak M, et al. Bone marrow cells and cd117-positive haematopoietic stem cells promote corneal wound healing. Acta Ophthalmol (Copenh). 2012;90:e367–73.CrossRefGoogle Scholar
  6. 6.
    Wells SJ, Bray RA, Stempora LL, Farhi DC. Cd117/cd34 expression in leukemic blasts. Am J Clin Pathol. 1996;106:192–5.PubMedGoogle Scholar
  7. 7.
    Shen HQ, Tang YM, Song H, Shi SW, Yang SL, Xu WQ, Qian BQ: [expressions of cd117 and cd11b in patients with apl at diagnosis and post-treatment]. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = Journal of experimental hematology/Chinese Association of Pathophysiology 2006;14:644–648Google Scholar
  8. 8.
    Rossi G, Nomdedeu Guinot JF, Fontana A, Minervini MM, Garcia-Dabrio MC, Cascavilla N. Cd117-cd15 in acute myeloid leukemia: no role as laip in the study of minimal residual disease. Eur J Haematol. 2013;90:171–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Massa S, Balciunaite G, Ceredig R, Rolink AG. Critical role for c-kit (cd117) in t cell lineage commitment and early thymocyte development in vitro. Eur J Immunol. 2006;36:526–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, et al. Expression of the c-kit receptor (cd117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (aml), including cytogenetically good-risk aml, and lacks prognostic significance. Leukemia Lymphoma. 1999;34:85–94.PubMedGoogle Scholar
  11. 11.
    Hans CP, Finn WG, Singleton TP, Schnitzer B, Ross CW. Usefulness of anti-cd117 in the flow cytometric analysis of acute leukemia. Am J Clin Pathol. 2002;117:301–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Drenou B, Fardel O, Fauchet R, Amiot L. Flow cytometry: application for the diagnosis and the follow-up of hematological malignancies. Annales De Biologie Clinique. 2002;60:663–72.PubMedGoogle Scholar
  13. 13.
    Hoehn D, Medeiros LJ, Chen SS, Tian T, Jorgensen JL, Ahmed Y, et al. Cd117 expression is a sensitive but nonspecific predictor of flt3 mutation in t acute lymphoblastic leukemia and t/myeloid acute leukemia. Am J Clin Pathol. 2012;137:213–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Martinez A, Aymerich M, Castillo M, Colomer D, Bellosillo B, Campo E, et al. Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. Cytometry Part B, Clin Cytom. 2003;56:8–15.CrossRefGoogle Scholar
  15. 15.
    Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (egil). Blood. 1998;92:596–9.PubMedGoogle Scholar
  16. 16.
    Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (egil). Leukemia. 1995;9:1783–6.PubMedGoogle Scholar
  17. 17.
    Muroi K, Nakamura M, Amemiya Y, Suda T, Miura Y. Expression of c-kit receptor (cd117) and cd34 in leukemic cells. Leukemia Lymphoma. 1995;16:297–305.CrossRefPubMedGoogle Scholar
  18. 18.
    Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA. Expression of a 150-kd cell surface antigen identified by monoclonal antibody yb5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res. 1988;12:923–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Vakiani E, Cattoretti G, Colovai AI, Murty VV, Alobeid B, Bhagat G. Cd117 expression in diffuse large b-cell lymphomas: fact or fiction? Pathol Int. 2005;55:716–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Valverde LR, Matutes E, Farahat N, Heffernan A, Owusu-Ankomah K, Morilla R, et al. C-kit receptor (cd117) expression in acute leukemia. Ann Hematol. 1996;72:11–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Nomdedeu JF, Mateu R, Altes A, Llorente A, Rio C, Estivill C, et al. Enhanced myeloid specificity of cd117 compared with cd13 and cd33. Leuk Res. 1999;23:341–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Abbas Ahmadi
    • 1
  • Ali-Akbar Poorfathollah
    • 2
  • Mahnaz Aghaiipour
    • 3
  • Mansour Rezaei
    • 4
  • Mahin Nikoo-ghoftar
    • 3
  • Mohammad Abdi
    • 5
  • Alireza Gharib
    • 6
  • Amir Amini
    • 7
  1. 1.Cellular and Molecular Research CenterKurdistan University of Medical SciencesSanandajIran
  2. 2.Immunology DepartmentTarbiat Modares UniversityTehranIran
  3. 3.Flowcytometry DepartmentIranian Blood Transfusion OrganizationTehranIran
  4. 4.Biostatistics DepartmentKermanshah University of Medical SciencesKermanshahIran
  5. 5.Department of Pathology and Medical Laboratory Sciences, Para-Medicine FacultyKurdistan University of Medical SciencesSanandajIran
  6. 6.Deputy of Research and TechnologyKurdistan University of Medical SciencesSanandajIran
  7. 7.Exercise Physiology Research CenterBaqiyatallah University of Medical SciencesTehranIran

Personalised recommendations